{"nctId":"NCT00217438","briefTitle":"Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma","startDateStruct":{"date":"2005-07"},"conditions":["Refractory Multiple Myeloma","Stage II Multiple Myeloma","Stage III Multiple Myeloma"],"count":130,"armGroups":[{"label":"Arm I (high dose melphalan, amifostine trihydrate, transplant)","type":"EXPERIMENTAL","interventionNames":["Drug: melphalan","Drug: amifostine trihydrate","Procedure: peripheral blood stem cell transplantation","Genetic: fluorescence in situ hybridization","Procedure: bone marrow ablation with stem cell support"]},{"label":"Arm II (low dose melphalan, amifostine trihydrate, transplant)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: melphalan","Drug: amifostine trihydrate","Procedure: peripheral blood stem cell transplantation","Genetic: fluorescence in situ hybridization","Procedure: bone marrow ablation with stem cell support"]}],"interventions":[{"name":"melphalan","otherNames":["Alkeran","CB-3025","L-PAM","L-phenylalanine mustard","L-Sarcolysin"]},{"name":"amifostine trihydrate","otherNames":["ethiofos","Ethyol","gammaphos","WR-2721"]},{"name":"peripheral blood stem cell transplantation","otherNames":["PBPC transplantation","PBSC transplantation","peripheral blood progenitor cell transplantation","transplantation, peripheral blood stem cell"]},{"name":"fluorescence in situ hybridization","otherNames":["fluorescence in situ hybridization (FISH)"]},{"name":"bone marrow ablation with stem cell support","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who have MM undergoing autologous or syngeneic hematopoietic transplantation\n* Patients must meet Salmon and Durie criteria for initial diagnosis of MM\n* Transplant will be offered to patients with stage II or III MM\n* Measurable disease, defined as serum monoclonal protein \\>= 0.2 g/dl or Bence Jones protein \\>= 200 mg/24 h\n* Karnofsky \\>= 70 or Eastern Cooperative Oncology Group (ECOG) 0-2\n* Life expectancy is not severely limited by concomitant illness\n* Left ventricular ejection fraction \\>= 50%\n* No uncontrolled arrhythmias or symptomatic cardiac disease\n* Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and diffusion capacity of carbon monoxide (DLCO) \\>= 50%\n* No symptomatic pulmonary disease\n* Human immunodeficiency virus (HIV) negative\n* Bilirubin \\< 2 mg/dl\n* Serum glutamic pyruvate transaminase (SGPT) \\< 2.5 x normal\n* Creatinine clearance \\>= 60 cc/min, estimated or measured\n* Signed informed consent\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Uncontrolled infection\n* Planned tandem autologous/reduced intensity allograft\n* Insufficient PBSC for an autologous transplant (\\< 3.0 x 10\\^6 CD34+ cells/kg total)\n* Prior autologous transplant\n* Non-secretory myeloma and patients who are in a complete response or near complete response after conventional therapy\n* Patients unwilling to practice adequate forms of contraception if clinically indicated\n* Male patients on study need to be consulted to use latex condoms, even if they have had a vasectomy, every time they have sex with a woman who is able to have children\n* Patients with history of seizures\n* Patients receiving antihypertensive therapy that cannot be stopped for 24 hours preceding amifostine treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"CR and Near CR Rates","description":"Per modified European Group for Blood and Marrow Transplant (EBMT) response criteria for definition of response in patients with multiple myeloma treated by high-dose therapy and stem cell transplantation: Complete Response (CR): Complete disappearance of all clinically measurable disease, complete response requires negative tests for monoclonal proteins in serum and urine by immunofixation, no monoclonal plasma cells in marrow specimen by flow cytometry and no evidence of progressive bone disease by skeletal survey. \"Near\" Complete Response (nCR): Less than 0.1 gram/dL monoclonal protein detectable in serum by standard protein electrophoresis and less than 50 mg monoclonal protein detectable in urine on 24 hour collection. Less than 5% monoclonal plasma cells detectable in bone marrow by immunohistochemistry. No evidence of progressive bone disease by skeletal survey.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Toxicities Between Melphalan 280 mg/m^2 or Melphalan 200 mg/m^2","description":"Number of Grade 3-4 adverse events observed in each group from enrollment through the Day 80-120 evaluation. Grade 3-4 events are defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":66},"commonTop":["Mucositis-Grade 3 or higher","Diarrhea","Nausea/Vomiting","Atrial fibrillation","Pulmonary embolism"]}}}